Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An announcement from Day One Biopharmaceuticals ( (DAWN) ) is now available.
Samuel Blackman, co-founder of Day One Biopharmaceuticals, plans to retire as Head of Research & Development by the end of 2024, transitioning to a strategic advisor role. His departure marks a significant leadership change as the company searches for his successor, acknowledging his pivotal contributions since its inception.
See more insights into DAWN stock on TipRanks’ Stock Analysis page.